Cargando…

NEDD4L binds the proteasome and promotes autophagy and bortezomib sensitivity in multiple myeloma

Multiple myeloma (MM) remains an incurable plasma cell cancer characterized by abnormal secretion of monoclonal immunoglobulins. The molecular mechanism that regulates the drug sensitivity of MM cells is being intensively studied. Here, we report an unexpected finding that the protein encoded by neu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Xi, Cao, Wen, Yao, Shunnan, Chen, Jing, Liu, Yang, Qu, Jianwei, Li, Yi, Han, Xiaoyan, He, Jingsong, Huang, He, Zhang, Enfan, Cai, Zhen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8891287/ https://www.ncbi.nlm.nih.gov/pubmed/35236820 http://dx.doi.org/10.1038/s41419-022-04629-8

Ejemplares similares

TRIM21 enhances bortezomib sensitivity in multiple myeloma by halting prosurvival autophagy
por: Chen, Jing, et al.
Publicado: (2023)

The NEDD4‐1 E3 ubiquitin ligase: A potential molecular target for bortezomib sensitivity in multiple myeloma
por: Huang, Xi, et al.
Publicado: (2019)

Pirh2 mediates the sensitivity of myeloma cells to bortezomib via canonical NF-κB signaling pathway
por: Yang, Li, et al.
Publicado: (2018)

The many substrates and functions of NEDD4-1
por: Huang, Xi, et al.
Publicado: (2019)

BAFF is involved in macrophage-induced bortezomib resistance in myeloma
por: Chen, Jing, et al.
Publicado: (2017)

Dihydroartemisinin Modulates Apoptosis and Autophagy in Multiple Myeloma through the P38/MAPK and Wnt/β-Catenin Signaling Pathways
por: Wu, Xiuhua, et al.
Publicado: (2020)

The adverse impact of a gain in chromosome 1q on the prognosis of multiple myeloma treated with bortezomib-based regimens: A retrospective single-center study in China
por: Chen, Qingxiao, et al.
Publicado: (2022)

Different Patient Subgroup Different Maintenance, Proteasome Inhibitors or Immunomodulators Maintenance for Newly Diagnosed Multiple Myeloma: A 7-Year Single-Center Data in China
por: Han, Xiaoyan, et al.
Publicado: (2021)

Corrigendum: Different Patient Subgroup Different Maintenance, Proteasome Inhibitors or Immunomodulators Maintenance for Newly Diagnosed Multiple Myeloma: A 7-Year Single-Center Data in China
por: Han, Xiaoyan, et al.
Publicado: (2021)

Efficacy of Intermittent, Oral Famciclovir Prophylaxis for Bortezomib-Induced Herpes Zoster in Multiple Myeloma Patients
por: Zheng, Gaofeng, et al.
Publicado: (2022)

The Choice of Regimens Based on Bortezomib for Patients with Newly Diagnosed Multiple Myeloma
por: He, Jingsong, et al.
Publicado: (2014)

CCL2 promotes macrophages-associated chemoresistance via MCPIP1 dual catalytic activities in multiple myeloma
por: Xu, Ruyi, et al.
Publicado: (2019)

Identification of key candidate genes and pathways in multiple myeloma by integrated bioinformatics analysis
por: Yan, Haimeng, et al.
Publicado: (2019)

Sensitizing human multiple myeloma cells to the proteasome inhibitor bortezomib by novel curcumin analogs
por: MUJTABA, TASKEEN, et al.
Publicado: (2012)

Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance
por: Kraus, M, et al.
Publicado: (2013)

Bortezomib-Based Regimens for Newly Diagnosed Multiple Myeloma in China: A Report of 12-Year Real-World Data
por: He, Jingsong, et al.
Publicado: (2020)

Chidamide and venetoclax synergistically exert cytotoxicity on multiple myeloma by upregulating BIM expression
por: Cao, Liqin, et al.
Publicado: (2022)

Bortezomib Treatment Modulates Autophagy in Multiple Myeloma
por: Di Lernia, Giuseppe, et al.
Publicado: (2020)

Metabolic reprogramming in macrophage responses
por: Liu, Yang, et al.
Publicado: (2021)

Integrated bioinformatic analysis of HNF1A in human cancers
por: Zhang, Enfan, et al.
Publicado: (2021)

Overcoming Proteasome Inhibitor-Refractory Multiple Myeloma With Elotuzumab, Bortezomib, Nelfinavir, and Dexamethasone
por: Erath, Alexandra, et al.
Publicado: (2020)

Myeloma-derived IL-32γ induced PD-L1 expression in macrophages facilitates immune escape via the PFKFB3-JAK1 axis
por: Liu, Yang, et al.
Publicado: (2022)

Solamargine induces autophagy‐mediated apoptosis and enhances bortezomib activity in multiple myeloma
por: Han, Qiaoyan, et al.
Publicado: (2022)

How are MCPIP1 and cytokines mutually regulated in cancer-related immunity?
por: Xu, Ruyi, et al.
Publicado: (2020)

RNA demethylase ALKBH5 in cancer: from mechanisms to therapeutic potential
por: Qu, Jianwei, et al.
Publicado: (2022)

Predicting the response of multiple myeloma to the proteasome inhibitor Bortezomib by evaluation of the unfolded protein response
por: Nikesitch, N, et al.
Publicado: (2016)

Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma
por: Richardson, P G, et al.
Publicado: (2017)

Therapeutic effects of the novel subtype-selective histone deacetylase inhibitor chidamide on myeloma-associated bone disease
por: He, Jingsong, et al.
Publicado: (2018)

The Role of Chaperone-Mediated Autophagy in Bortezomib Resistant Multiple Myeloma
por: Nikesitch, Nicholas, et al.
Publicado: (2021)

RNA demethylase ALKBH5 promotes tumorigenesis in multiple myeloma via TRAF1-mediated activation of NF-κB and MAPK signaling pathways
por: Qu, Jianwei, et al.
Publicado: (2021)

Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to Ixazomib
por: Manda, Sudhir, et al.
Publicado: (2020)

Correction: Pomalidomide, bortezomib, and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma
por: Richardson, P. G., et al.
Publicado: (2018)

ClC5 Decreases the Sensitivity of Multiple Myeloma Cells to Bortezomib via Promoting Prosurvival Autophagy
por: Zhang, Huimin, et al.
Publicado: (2018)

Bortezomib Amplifies Effect on Intracellular Proteasomes by Changing Proteasome Structure()
por: Pitcher, David S., et al.
Publicado: (2015)

The resistance mechanisms of proteasome inhibitor bortezomib
por: Lü, Shuqing, et al.
Publicado: (2013)

Multiple Extramedullary-Bone Related and/or Extramedullary Extraosseous Are Independent Poor Prognostic Factors in Patients With Newly Diagnosed Multiple Myeloma
por: He, JingSong, et al.
Publicado: (2021)

Targeting MAGE-C1/CT7 Expression Increases Cell Sensitivity to the Proteasome Inhibitor Bortezomib in Multiple Myeloma Cell Lines
por: de Carvalho, Fabricio, et al.
Publicado: (2011)

Upregulation of Protein Synthesis and Proteasome Degradation Confers Sensitivity to Proteasome Inhibitor Bortezomib in Myc-Atypical Teratoid/Rhabdoid Tumors
por: Tran, Huy Minh, et al.
Publicado: (2020)

Down-Regulation of CD9 by Methylation Decreased Bortezomib Sensitivity in Multiple Myeloma
por: Hu, Xiaotong, et al.
Publicado: (2014)

The Proteasome Inhibitor Bortezomib Sensitizes AML with Myelomonocytic Differentiation to TRAIL Mediated Apoptosis
por: van Dijk, Marianne, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_khg9ba4h7ec2t987afroragckl